Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
Abstract
Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
Claims
exact text as granted — not AI-modified1 . A method for identifying a tumor antigen comprising:
co-culturing tumor material isolated from a subject with peripheral blood mononuclear cells (PBMCs) in the presence of an IL-21 composition and antigen presenting cells (APCs); isolating a T cell population from the culture; cloning individual T cells from the T cell population; and characterizing T cell clones for antigen-specificity.
2 . The method of claim 1 , wherein the T cell population is a T cell population that is non-terminally differentiated.
3 . The method of claims 1 , wherein the PBMCs or T cell population is an autologous cell population.
4 . The method of claim 1 , wherein the tumor material comprises total RNA, lysed tumor cells or apoptotic bodies.
5 . The method of claim 2 , wherein the isolated T cell population does not include CD4+ cells.
6 . The method of claim 1 , wherein co-culturing is in the presence of the IL-21 composition and one or more additional cytokines
7 . A method of preparing a naïve CD8+ human T cell population for in use adoptive immunotherapy comprising:
isolating peripheral blood mononuclear cells (PBMCs) from a biological sample; identifying PBMCs having a histocompatible phenotype to a subject having a tumor; isolating a naïve CD8+ human T cell population; co-culturing tumor material isolated from the subject with the naïve CD8+ human T cell population in the presence of an IL-21 composition and antigen presenting cells (APCs); and expanding the cells in culture.
8 . The method of claim 7 , wherein the PBMCs are autologous.
9 . The method of claim 7 , wherein after the step of co-culturing the tumor material and with the T cell population, the T cells are enriched.
10 . A method of preparing a naïve CD8+ human T cell population for use in adoptive immunotherapy comprising:
isolating a biological sample containing T cells; identifying a T cell population having a histocompatible phenotype to a subject having a tumor; isolating a naïve CD8+ human T cell population; co-culturing tumor material from the subject with the naïve CD8+ human T cell population in the presence of an IL-21 composition and APCs; and expanding these cells in culture.
11 . The method of claim 10 , wherein the T cell population is autologous.
12 . The method of claim 7 , 10 , or 16 wherein the tumor material comprises total RNA, lysed tumor cells or apoptotic bodies.
13 . The method of claim 10 , wherein after the step of co-culturing the tumor material and with the T cell population, the T cells are enriched.
14 . A method for ex vivo expansion of antigen-specific cytotoxic T cells comprising:
isolating a biological sample containing T cells; identifying a T cell population having a histocompatible phenotype to a subject; co-culturing antigenic material from the subject with the T cell population in the presence of an IL-21 composition; expanding the cells in culture; and and reintroducing the cells back into the subject.
15 . The method of claim 14 , wherein after the step of co-culturing the tumor material and with the T cell population, the T cells are enriched.
16 . A method of preparing a non-terminally differentiated CD8+ human T cell population for use in adoptive immunotherapy comprising:
isolating a biological sample containing T cells; identifying a T cell population having a histocompatible phenotype to a subject having a tumor; isolating a non-terminally differentiated CD8+ human T cell population; co-culturing tumor material from the subject with the non-terminally differentiated CD8+ human T cell population in the presence of an IL-21 composition and APCs; and expanding these cells in culture.
17 . The method of claim 16 , wherein the T cell population is autologous.Join the waitlist — get patent alerts
Track US2010310533A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.